FTSE MIB
33.769,31 +22,65 (+0,07%) Dow Jones
37.903,29 +87,37 (+0,23%) Nasdaq
15.605,48 -52,34 (-0,33%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
79,58 +0,58 (+0,73%) Bitcoin EUR
53.875,48 +248,92 (+0,46%)
Titan Pharmaceuticals, Inc. (TTNP)
| Chiusura precedente | 6,71 |
| Aperto | 6,75 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 6,70 - 6,75 |
| Intervallo di 52 settimane | 5,00 - 16,60 |
| Volume | |
| Media Volume | 8.360 |
| Capitalizzazione | 6,125M |
| Beta (5 anni mensile) | 1,35 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -7,41 |
| Prossima data utili | 01 apr 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireTitan Pharmaceuticals Announces $9.5 Million Private Placement of Convertible Preferred Stock
SAN FRANCISCO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that it has entered into a definitive securities purchase agreement (the “Purchase Agreement”) with The Sire Group Ltd. (“Sire Group”) for the sale of the Company’s newly designated Series AA Convertible Preferred Stock (the “Preferred Stock”). Sire Group purchased 950,000 shares of Preferred Stock for an aggregate purchase price of $9,500,000, consisting of (i)
- GlobeNewswire
Titan Pharmaceuticals Announces Sale of Certain ProNeura Assets
Company to receive $2 million in upfront payments, with the potential to receive up to $50 million in milestone payments and single digit royalty payments on future net salesSAN FRANCISCO, July 27, 2023 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into an Asset Purchase Agreement (the “Agreement”) with Fedson, Inc., a Delaware Corporation (“Fedson”), for the sale of certain ProNeura assets including Titan’s portfoli
